GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

DNA TOPOISOMERASES &LATE CELL CYCLE CHECKPOINTS

$3,065
University Of Calif-Los Alamos Nat Lab · P41 · FY2000 · RR

Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung Cancer

$3,000
Brian J Thomas · University Of Missouri-Columbia · F30 · FY2025 · CA

p27pTpT drives cancer-promoting inflammation and shapes the tumor microenvironment (TME) toward a more tumor-permissive state in vivo

$3,000
Seyedehfatemeh Razavipour · Georgetown University · F99 · FY2025 · CA

Program 4: Leukemia

$2,949
David Marc Weinstock · Dana-Farber Cancer Inst · P30 · FY2020 · CA

Program 30: Neuro-Oncology

$2,948
Charles Stiles · Dana-Farber Cancer Inst · P30 · FY2020 · CA

Signal Transduction Research Program

$2,857
Daniel Peter Petrylak · Yale University · P30 · FY2018 · CA

Cancer Immunology Research Program

$2,857
Lieping Chen · Yale University · P30 · FY2018 · CA

Cancer Immunology Research Program

$2,683
Lieping Chen · Yale University · P30 · FY2018 · CA

Signal Transduction Research Program

$2,682
Daniel Peter Petrylak · Yale University · P30 · FY2018 · CA

Identifying Effective Immune Checkpoint Therapy Strategies in Triple Negative Breast Cancer

$2,528
Daniel Patrick Hollern · Univ Of North Carolina Chapel Hill · F32 · FY2017 · CA

BIOCHEMICAL STUDIES OF HUMAN DNA POLYMERASE DELTA

$2,425
Marietta Y. Lee · University Of Washington · P41 · FY2010 · RR

Translational & Clinical Research (TACR) Program

$2,399
Muneesh Tewari · University Of Michigan At Ann Arbor · P30 · FY2018 · CA

Cancer Immunology Program - 03

$2,068
Drew M. Pardoll · Johns Hopkins University · P30 · FY2018 · CA

Breast and Ovarian Cancer Program - 08

$2,067
Vered Stearns · Johns Hopkins University · P30 · FY2018 · CA

MRA Melanoma Models Workshop

$2,000
Marc S Hurlbert · Melanoma Research Alliance Foundation · R13 · FY2020 · CA

Robust Predictor of Breast Cancer Risk

$2,000
Harry Ostrer · Morgan And Mendel Genomics, Inc. · R41 · FY2018 · CA

Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas

$1,625
George Yancey Gillespie · Treovir, Inc · R44 · FY2022 · CA

Program 4: Leukemia

$1,602
Benjamin Levine Ebert · Dana-Farber Cancer Inst · P30 · FY2018 · CA

Program 30: Neuro-Oncology

$1,602
Charles Stiles · Dana-Farber Cancer Inst · P30 · FY2018 · CA

Personalized precision dosing of biologic therapies in oncology

$1,450
Bradley T Messmer · Abreos Biosciences, Inc. · R44 · FY2019 · CA

Characterization of Altered Immunity in Patients with Inflammatory Arthritis Induced by Immune Checkpoint Inhibitor Therapy

$1,000
Sang Taek Kim · Yale University · K08 · FY2024 · AR

Human Immune Monitoring Shared Resource

$3
Richard D Schulick · University Of Colorado Denver · P30 · FY2022 · CA

Targeting Unique Myeloid Populations to Overcome Anti-PD-1 Resistance Conferred by Specific Cancer Mutations

$1
Brian C Miller · Harvard Medical School · K08 · FY2021 · CA

Adoptive T Cell Therapy for Pancreatic Cancer

$1
Cassian Yee · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Center for Lupus Research

$1
Maria Virginia Pascual · Baylor Research Institute · P50 · FY2009 · AR